Perigon Wealth Management LLC Decreases Stake in Lantern Pharma Inc. (NASDAQ:LTRN)

Perigon Wealth Management LLC cut its holdings in Lantern Pharma Inc. (NASDAQ:LTRN) by 49.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 14,600 shares of the company’s stock after selling 14,300 shares during the period. Perigon Wealth Management LLC owned 0.14% of Lantern Pharma worth $47,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP increased its position in shares of Lantern Pharma by 55.7% in the second quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock valued at $86,000 after acquiring an additional 6,585 shares during the period. Renaissance Technologies LLC lifted its stake in shares of Lantern Pharma by 24.5% in the second quarter. Renaissance Technologies LLC now owns 81,800 shares of the company’s stock worth $382,000 after buying an additional 16,100 shares in the last quarter. Finally, Westside Investment Management Inc. raised its holdings in shares of Lantern Pharma by 166.5% during the third quarter. Westside Investment Management Inc. now owns 30,650 shares of the company’s stock valued at $112,000 after purchasing an additional 19,150 shares during the last quarter. 28.62% of the stock is owned by institutional investors.

Lantern Pharma Stock Performance

NASDAQ:LTRN opened at $4.67 on Tuesday. Lantern Pharma Inc. has a 52-week low of $2.79 and a 52-week high of $11.99. The firm has a market capitalization of $50.37 million, a PE ratio of -2.62 and a beta of 1.54. The stock has a 50-day simple moving average of $3.71 and a two-hundred day simple moving average of $3.76.

Lantern Pharma (NASDAQ:LTRN) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.14. During the same quarter in the prior year, the company posted ($0.29) earnings per share. Equities analysts forecast that Lantern Pharma Inc. will post -1.9 earnings per share for the current fiscal year.

Lantern Pharma Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.